TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens
Yuichi Hikichi(Takeda (United States)), Erik Kupperman(Alexion Pharmaceuticals (United States))
Cited by 77
Related Papers
No related papers found
Powered by citation graph analysis